Loading...
XSHE
300086
Market cap483mUSD
Jul 25, Last price  
7.61CNY
1D
0.66%
1Q
64.72%
Jan 2017
-45.33%
IPO
-45.02%
Name

Honz Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
300.39
P/S
4.68
EPS
0.03
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-3.48%
Revenues
740m
+38.05%
95,940,150135,846,194218,779,083314,451,808304,241,891368,780,279309,337,001408,538,464409,757,276471,474,596480,831,720882,744,8031,008,431,482921,642,902836,565,805535,745,365739,569,815
Net income
12m
34,197,59049,524,79297,577,158139,317,546022,580,53314,852,93562,092,44668,311,10546,156,62550,196,88613,366,21809,339,25210,987,504011,529,863
CFO
71m
+141.09%
30,589,23862,607,03893,576,12879,893,9720109,459,62678,928,79873,930,32278,297,41590,883,87118,172,221157,658,19145,059,857011,329,33629,322,90570,693,705
Dividend
Aug 13, 20210.02 CNY/sh

Profile

Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pediatric medicines in China. It offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine. The company markets its products through a network of agents and sales terminals. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. is headquartered in Guangzhou, China.
URL
http://www.honz.com.cn
IPO date
May 26, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
739,570
38.05%
535,745
-35.96%
Cost of revenue
570,956
581,752
Unusual Expense (Income)
NOPBT
168,614
(46,006)
NOPBT Margin
22.80%
Operating Taxes
18,277
Tax Rate
10.84%
NOPAT
150,337
(46,006)
Net income
11,530
 
Dividends
(24,344)
Dividend yield
0.92%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
176,661
240,272
Long-term debt
324,978
342,846
Deferred revenue
48,179
51,002
Other long-term liabilities
1
1
Net debt
351,941
31,892
Cash flow
Cash from operating activities
70,694
29,323
CAPEX
(137,559)
Cash from investing activities
(59,478)
13,382
Cash from financing activities
(131,789)
FCF
(43,240)
82,635
Balance
Cash
144,398
269,812
Long term investments
5,300
281,413
Excess cash
112,720
524,438
Stockholders' equity
483,264
596,116
Invested Capital
1,815,122
1,440,198
ROIC
9.24%
ROCE
8.60%
EV
Common stock shares outstanding
450,385
450,000
Price
5.87
-5.63%
6.22
-28.34%
Market cap
2,643,762
-5.55%
2,799,000
-28.34%
EV
3,028,967
2,870,218
EBITDA
246,039
4,239
EV/EBITDA
12.31
677.13
Interest
25,405
27,400
Interest/NOPBT
15.07%